(TNGX) Tango Therapeutics - Ratings and Ratios

Tango Therapeutics, a pioneering precision oncology company, is revolutionizing the field of cancer treatment by developing targeted therapies for specific patient populations with unmet medical needs. The companys innovative pipeline includes PRMT5 inhibitors, such as TNG462, currently in Phase 1/2 clinical trials for pancreatic and lung cancer, and TNG456, a brain-penetrant PRMT5 inhibitor designed to combat glioblastoma. Additionally, TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor, is being developed to counteract the immune evasion effects of serine-threonine kinase 11 loss-of-function mutations in lung cancer.

With a strong foundation in cancer genomics and a robust pipeline, Tango Therapeutics is poised for significant growth. The companys focus on precision oncology and its commitment to addressing unmet medical needs have garnered attention from investors and industry experts alike. As a publicly traded company listed on NASDAQ under the ticker symbol TNGX, Tango Therapeutics is well-positioned to capitalize on its innovative research and development.

Analyzing the technical data, the stock has shown a significant uptrend, with the last price of $4.92 exceeding the SMA20 of $4.23, indicating a potential bullish momentum. The SMA50 and SMA200 are $2.60 and $3.62, respectively, suggesting a long-term uptrend. The ATR of 0.55, equivalent to 11.16% of the last price, indicates moderate volatility. Given the current trend and volatility, a potential price target could be $7.50, representing a 52% increase from the current price.

From a fundamental analysis perspective, Tango Therapeutics has a market capitalization of $520.83M USD, with a negative P/E ratio due to the companys current losses. The lack of a forward P/E ratio suggests that the company is not yet profitable, and the market is likely pricing in future growth. The RoE of -62.75% indicates significant losses, but this is not uncommon for companies in the biotechnology sector, particularly those with promising pipelines. As the company progresses with its clinical trials and potentially brings new therapies to market, the stock may experience significant growth. Based on the fundamental data, a forecast for the stock price could be $10.00, representing a 103% increase, if the company achieves significant milestones in its clinical trials and demonstrates a clear path to profitability.

Combining the technical and fundamental analysis, a potential forecast for TNGX could be a price target of $9.00 within the next 12-18 months, representing a 83% increase from the current price. This forecast is based on the companys promising pipeline, the current uptrend, and the potential for significant growth as the company progresses with its clinical trials and brings new therapies to market.